Negative in Ames, mouse lymphoma and rat and mouse micronucleus assays
“Vericiguat was not genotoxic in the in vitro microbial mutagenicity (Ames) assay, the in vitro mouse lymphoma assay and the in vivo rat and mouse micronucleus assay.”
“Carcinogenicity was evaluated in 2-year studies conducted in CD1 mice and Wistar rats. Vericiguat did not show a carcinogenic effect in mice dosed up to 150 mg/kg/day (males) or up to 250 mg/kg/day (females).”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rabbit EFD: cardiac ventricular septal defect and truncus arteriosus at ≥2.5 mg/kg/day (≥4x MRHD exposure)
“An increased incidence of cardiac ventricular septal defect along with truncus arteriosus communis was observed at ≥2.5 mg/kg/day, which is ≥4 times the human exposure at the MRHD.”
Dog telemetry: PR interval effect with heart-rate change, possible QRS effect, no QT/QTc effect
“The cardiovascular safety pharmacology in telemetered dogs indicated an effect on the PR interval concurrent with a change in heart rate, possibly an effect on the QRS complex but no effect on QT/QTc intervals.”
“Vericiguat was not genotoxic in the in vitro microbial mutagenicity (Ames) assay, the in vitro mouse lymphoma assay and the in vivo rat and mouse micronucleus assay.”
“Vericiguat was not genotoxic in the in vitro microbial mutagenicity (Ames) assay, the in vitro mouse lymphoma assay and the in vivo rat and mouse micronucleus assay.”
“Vericiguat was not genotoxic in the in vitro microbial mutagenicity (Ames) assay, the in vitro mouse lymphoma assay and the in vivo rat and mouse micronucleus assay.”
hERG IC50 ~10 µM, 546-fold margin; assay deviated from ICH S7B Q&A best practices
“A suboptimal in vitro assay showed the parent drug to be a moderate inhibitor of the hERG channel with an IC50 of 10µM. Although the safety margin of vericiguat on hERG current is high (546-fold), the hERG assay deviates significantly from the new ICH S7B Q&A best practices.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative